POSTERIOR SUB-TENON'S Avastin

Diffuse Diabetic Macular Edema Clinical Trial

Official title:

POSTERIOR SUB-TENON'S CAPSULE INJECTION OF BEVACIZUMAB FOR TREATMENT OF DIFFUSE DIABETIC MACULAR EDEMA

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT00567372
• Other study ID #: 00922
• Status: Withdrawn
• Phase: Phase 4
• Start date: June 2008
• Est. completion date: June 2009

Study information

• Verified date: May 2024
• Source: Asociación para Evitar la Ceguera en México
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Posterior sub-tenon's injection of bevacizumab decreased diffuse diabetic macular edema

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: June 2009
• Est. primary completion date: November 2008
• Accepts healthy volunteers: No
• Gender: All
• Age group: 25 Years to 90 Years

Eligibility

Inclusion Criteria:

Patients with diffuse diabetic macular edema non-proliferative diabetic retinopathy Maculat thickness =250 µ BCVA = 20/400 Without any treatment

Related Conditions & MeSH terms

• Diffuse Diabetic Macular Edema
• Edema
• Macular Edema

Intervention

Drug:
• bevacizumab (Sub-tenon´s injection)
a single posterior sub-tenon's capsule injection of bevacizumab (2.5 mg /0.1ml)

Locations

Country	Name	City	State
Mexico	Asociación para Evitar la Ceguera en Mexico	Mexico DF	DF

Sponsors (1)

Lead Sponsor	Collaborator
Asociación para Evitar la Ceguera en México

Country where clinical trial is conducted

Mexico, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	macular volume		baseline, 3,6 and 12 weeks
Secondary	macular thickness		baseline,3,6 and 12 weeks
Secondary	best corrected visual acuity		baseline, 3,6 and 12 weeks